Influential government advisers will debate Friday if there’s enough proof that a booster dose of Pfizer’s COVID-19 vaccine is safe and effective \u2014 the first step toward deciding which Americans need one and when.<\/b>
\nWASHINGTON \u2014 Influential government advisers will debate Friday if there\u2019s enough proof that a booster dose of Pfizer\u2019s COVID-19 vaccine is safe and effective \u2014 the first step toward deciding which Americans need one and when. The Food and Drug Administration on Wednesday posted much of the evidence its advisory panel will consider. The agency struck a decidedly neutral tone on the rationale for boosters \u2014 an unusual and careful approach that\u2019s all the more striking after President Joe Biden and his top health advisers trumpeted a booster campaign they hoped to begin next week. Pfizer\u2019s argument: While protection against severe disease is holding strong in the U.S., immunity against milder infection wanes somewhere around six to eight months after the second dose. The company gave an extra dose to 306 people at that point and recorded levels of virus-fighting antibodies threefold higher than after the earlier shots. More important, Pfizer said, those antibodies appear strong enough to handle the extra-contagious delta variant that is surging around the country. To bolster its case, Pfizer pointed the FDA to data from Israel, which began offering boosters over the summer. That study tracked about 1 million people 60 and older and found those who got the extra shot were far less likely to become infected soon afterward. In the documents posted by the FDA, Pfizer said that translates to \u201croughly 95% effectiveness\u201d when delta was spreading, comparable to the protection seen shortly after the vaccine\u2019s rollout earlier in the year. The FDA\u2019s reviewers, however, suggested they would mainly look to research on how the vaccines are working among Americans, saying that \u201cmay most accurately represent vaccine effectiveness in the U.S. population.\u201d Overall, the data show that the Pfizer and other U.S.-authorized COVID-19 vaccines \u201cstill afford protection against severe COVID-19 disease and death in the United States,\u201d the agency said, summarizing the evidence. The FDA is not bound to follow the advice of its independent advisory panel. But if the agency overrules its own experts, that could stoke public confusion. Earlier this week, two top FDA vaccine regulators joined a group of international scientists in rejecting boosters now for otherwise healthy individuals, citing the strong continuing protection against severe disease. Cambridge-based Moderna submitted data to review effectiveness of its booster shot to the FDA and the European Medicines Agency earlier this month. The U.K. on Tuesday announced it would offer a third shot to everyone over age 50 beginning next week. Both Pfizer and Moderna boosters will be available for use there.<\/p>\n